NCT00335764View on ClinicalTrials.gov

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

February 28, 2010

Study Completion Date

September 30, 2012

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
Interventions
DRUG

sorafenib tosylate

given orally

DRUG

erlotinib hydrochloride

given orally

DRUG

tipifarnib

given orally

DRUG

temsirolimus

IV administration

Trial Locations (7)

10065

Memorial Sloan-Kettering Cancer Center, New York

15232

University of Pittsburgh, Pittsburgh

53792

University of Wisconsin Hospital and Clinics, Madison

77030

M D Anderson Cancer Center, Houston

90095

University of California at Los Angeles, Los Angeles

94115

University of California San Francisco, San Francisco

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00335764 - Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | Biotech Hunter | Biotech Hunter